Actively Recruiting
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Led by Yale University · Updated on 2026-03-24
30
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
CONDITIONS
Official Title
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with HIV
- Receive care at the Atlanta VA Healthcare System
- Aged 18 years or older
- Meet criteria for mild, moderate, or severe alcohol use disorder by DSM-5 Alcohol Symptom Checklist and AUDIT-C screen
- Have significant alcohol use with PEth > 20 ng/ml
- Prescribed five or more medications
- Have a cell phone or reliable contact number
- Can provide written informed consent
You will not qualify if you...
- Currently engaged in formal alcohol treatment including medications for alcohol use disorder
- Pregnant, nursing, or trying to conceive
- Have a life-threatening or unstable medical, surgical, or psychiatric condition preventing participation
- Untreated moderate to severe opioid use disorder
- Live out of state
- Unable to read or understand English
- History of serious hypersensitivity or adverse reaction to study medication
- Taking medications for diabetes that may interact with the study drug
- BMI less than 23
- Diagnosis of type 1 diabetes
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Severe gastrointestinal dysmotility including gastroparesis
- History of pancreatitis unless cause known and no longer a risk
- Severe gallbladder disease
- Known severe diabetic eye diseases such as proliferative diabetic retinopathy or macular edema
- Already prescribed the study medication at recruitment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Atlanta VA Medical Center
Decatur, Georgia, United States, 30033
Actively Recruiting
Research Team
E
E. Jennifer Edelman, MD, MHS
CONTACT
J
June-Marie Weiss, MA, MEd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here